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Abstract
Background: General Practitioners (GPs) are well placed to care for patients with (chronic) substance use problems.
This pilot was carried out to study the feasibility and usefulness of a continuous surveillance of substance use
problems among general practice patients. The objectives were (i) to describe variables with missing values
exceeding 1% and whether patients were reported without substance-related problems; (ii) the profile and the
magnitude of the patient population that is treated for substance use problems.
Methods: Observational study by the Belgian Network of Sentinel General Practices (SGP) in 2013. Baseline (at the
first encounter) and 7-month follow-up data were reported of all patients treated for substance use problems. Two
main measurements were type of substance use and patient status at follow-up. Multiple logistic regression analysis
was used to examine patient status at follow-up.
Results: Of 479 patients, 47.2% had problems with alcohol alone, 20.3% with prescription drugs, 16.7% with illicit
drugs other than heroin or methadone and 15.9% with heroin or methadone. Problems with alcohol alone were
more prevalent in Flanders (53.0%; 95% confidence interval (CI) 46.8–59.1%) than in Wallonia-Brussels (39.8%; 95% CI
33.1–46.8%), while problems with heroin or methadone were more prevalent in Wallonia-Brussels (27.0%; 95% CI 21.
1–33.5%) than in Flanders (7.1%; 95% CI 4.3–10.9%). At follow-up, 32.8% of the patients had dropped out, 29.0% had
discontinued GP treatment and 38.2% had continued GP treatment. Overall, 32.4% of 479 patients had continued
GP treatment for substance use problems during the study period. In Wallonia-Brussels, this proportion was higher
(42.7%; 95% CI 35.9–49.6%) than in Flanders (24.3%; 95% CI 19.2–29.8%).
Conclusions: A continuous surveillance of the general practice population treated for substance use problems
seems to be feasible and useful. The latter is suggested by the specific profile and the relative magnitude of the
population. Inter-regional health system differences should be taken into account to estimate the epidemiology of
substance use problems among general practice patients.
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Background
Substance abuse is increasingly recognised as a chronic
condition that is accompanied by multiple health harms
and social problems [1]. The life of many patients with
substance use problems is marked by cycles of recovery,
relapse, and repeated treatments before reaching stable
recovery, permanent disability or death [2]. General
practitioners (GPs) are well placed to care for these
patients since primary care is essentially first-contact
care, long-term person-focused care, comprehensive care
for most health problems and coordinated care if care
elsewhere is required [3]. The European Study of the
Epidemiology of Mental Disorders (ESEMeD) showed that
the majority of people who seek care for mental health
problems consult a primary caregiver [4]. ESEMeD found
that in Belgium 66% of people seeking care for alcohol use
disorders consulted a GP and 10% consulted only a GP.
Recent research supports the provision of screening and
brief interventions for hazardous alcohol use by GPs and
substitution treatment for problem drug use [5, 6].
This pilot was carried out to study the usefulness and
the feasibility of a continuous surveillance of substance
use problems in the general practice population. Baseline
and follow-up data from patients treated for substance
use problems were reported in 2013 by the Belgian
Network of Sentinel General Practices (SGP). Sentinel
surveillance is a system of public health surveillance that
aims to monitor and clarify the epidemiology of health
problems to inform public health policy. In Belgium,
94% of the population has a regular GP and 77% visits
their GP annually [7]. Therefore, GPs are considered to
be the second best source of public health information
after the general population.
There were two reasons for piloting this surveillance.
First, it was found that primary care physicians identify
fewer than half of patients with alcohol use disorder
when using clinical judgement, and that their medical
records were accurate in less than three out of ten [8].
In this study, we expect to overcome the problem of
non-recognition and thus non-reporting of patients with
substance use problems by including only treated pa-
tients. Second, general practice is not covered by the
Treatment Demand Indicator (TDI) register that was
established in 2011 to monitor the epidemiology of
substance-related problems in Belgium. The TDI register
collects data on new treatment episodes reported by care
providers offering treatment for substance-related prob-
lems. In contrast to other European TDI registers, treat-
ment by GPs is not included in the Belgian TDI register
[9]. Yet, the nature of primary care suggest that general
practice patients have less severe problems than those
treated in specialised care settings (not setting,) [10]. In
the domain of substance use problems, there is some
evidence that users of alcohol alone present less severe
problems than poly-substance users or drug users [11,
12]. There are also indications that GPs have negative at-
titudes towards users of illicit drugs [13]. Belgian GPs
find the use of alcohol and cannabis more socially ac-
ceptable than other drugs [14]. We thus assume that
general practice patients treated for substance use prob-
lems show a different profile compared to patients
treated in specialised care settings. Consequently, the
SGP surveillance would be of use, in complement to the
TDI register, to estimate the epidemiology of problem-
atic use of substances as reflected by treatment demand.
We also expect a different patient profile in Flanders
compared to Wallonia-Brussels due to the organisation
of health services. In Wallonia-Brussels the provision of
opiate substitution treatment (OST) by GPs is much
more common than in Flanders [15, 16].
In short, to pilot (i) the feasibility and (ii) the useful-
ness of a continuous surveillance study by the SGP the
following objectives were set:
(i).To describe variables with missing values exceeding
1% and whether patients were reported without
specific substance-related problems. Both can be
seen as indicators of data quality. The inclusion
of patients without any of the substance-related
problems displayed on the registration form
conflicts with the concept of “problematic use
of substances”.
(ii).To examine the profile and the magnitude of
the general practice population that is treated
for substance use problems, by their GP alone
or mixed with treatment by non-GP caregivers,
in Belgium and its regions. Type of substance use
is one measure describing the profile of the
population. The relative magnitude of the
population is described by a second measure,
patient status at follow-up, more exactly the
proportion of patients who continued substance
use treatment by their GP throughout the study
period. We examine if type of substance use is a
determinant of patient status at follow-up.
Methods
Settings and participants
The Belgian Network of SGP comprises approximately
150 general practices with one or more sentinel GPs who
purposively record routine clinical care data for the sur-
veillance of specific health problems or care delivery. Data
are reported weekly on standard registration forms for a
period of at least one year. Sentinel GPs are comparable to
non-sentinel GPs for age and gender and the countrywide
network covers 1.4 to 1.8% of the Belgian population [17].
This study was carried out on top of the regular 2013
program involving 139 SGP. All SGP were invited to
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participate in this “Pilot study of patients being treated
for problematic use of substances” by using an additional
registration form. Pilot participation (n = 104 SGP) was
not significantly associated with the SGP region, the
solo/group character of the SGP, nor the age of partici-
pating sentinel GPs (n = 181) within all the SGP. The
proportion of women sentinel GPs participating in the
pilot study (59 of 67, 88.1%) was higher than the propor-
tion of men (77 of 114, 67.5%) (p = 0.001).
Baseline data were collected during five months from
mid-May to mid-October 2013. Fifty-six percent of the
SGP were located in Flanders and 56% of the patients
were reported by Flemish SGP. Five-month follow-up
forms were sent out for all recorded patients. In February
2014, all 104 SGP who reported at least one patient with
substance use problems were sent a list of the reported
patients to be returned after correction, completion or
confirmation of its content. Due to database administra-
tion errors the intended follow-up time was delayed by
approximately two months (see results section). Inclusion
criteria and definitions were described on the registration
form. Sentinel GPs were asked to complete a registration
form “at the first contact with all new or regular patients
between 18 and 64 years old who received treatment or
counselling for problematic use of substances (alcohol,
illicit drugs or prescription drugs)”. We included the
working age population only as the study was designed in
collaboration with the UP TO DATE research consortium
investigating the role of occupational health services in
substance use problems [18].
We stated that the amount or frequency of substance
use was not to be reported as the study was focusing on
patients being treated for problematic use of substances.
We thus assumed that treatment for substance use was
a sufficient indicator of its problematic character and
did not further define “problematic use of substances”.
Variables and measures
Substances displayed on the SGP registration form were
alcohol, cannabis, opiates (heroin), methadone (or other
substitute), cocaine, ecstasy, psychostimulants (amphet-
amines), hypnotics, tranquillizers, opioid analgesics, and
“other substances”. The measure “type of substance use”
was based on a hierarchical classification of substances
into four mutually exclusive categories: 1) use of alcohol
alone; 2) use of hypnotics/sedatives, tranquillizers or
opioid analgesics, with or without alcohol; 3) use of can-
nabis, stimulants, hallucinogens, cocaine or other illicit
drugs but no heroin or methadone, with or without the
substances in the two previous categories; and 4) use of
heroin or methadone, with or without the previously
displayed substances. This classification was based on a
literature review and patterns of substance use observed
in the SGP data, for example 18 of 25 users of stimulants
also used heroin, cocaine, ecstasy or cannabis while only 1
of 31 users of opioid analgesics also did [19]. Although
methadone may be prescribed and used as intended by
the prescribing physician, it was classified as an illicit drug
based on its relation with heroin.
Three substance use characteristics were reported:
abstinence from substances in the last four weeks, the
length of problematic substance use in years and the
occurrence of substance-related problems. The latter
were grouped on the standard registration form and in
the analysis as physical problems, mental problems,
social problems and problems at work. Treatment his-
tory at baseline was described by two variables: whether
this was a new treatment episode (versus an ongoing)
and whether this was the first ever treatment. No criteria
were given to define the start and the end of a treatment
episode. Types of treatment listed on the registration form
were a brief intervention (defined on the form), non-
pharmacological or psychological treatment, pharmaco-
logical treatment or other treatment.
The measure “patient (treatment) status at follow-up”
was defined by five categories based on the occurrence
and timing of GP-patient encounters after baseline.
Patients without a follow-up report, i.e. having dropped
out from the study, were considered together with
patients not seen by the GP after baseline (1). In our
experience, it is likely that SGP did not return follow-up
reports for patients not seen after baseline. Patients were
considered as having discontinued the treatment if they
were seen after baseline but not in the four weeks pre-
ceding the follow-up report (2). Patients seen by the GPs
in the four weeks before the follow-up report were con-
sidered as having continued substance use treatment by
their GP (3–5), although there is no evidence for the
validity of the cut-off point of four weeks. Depending on
the care setting(s), they were classified as having received
non-GP treatment alone (3), mixed treatment, i.e. GP and
non-GP treatment (4) or GP treatment alone (5). We thus
considered the small number of patients who received
usual care from their GP without targeted treatment
for substance use problems as having continued GP
treatment.
Statistical analyses
All data are person-based. We used 95% binomial propor-
tion confidence intervals (CI) to describe patient popula-
tion characteristics and treatment status at follow-up by
region. Significant bivariate associations were examined by
multiple logistic regression. We used multiple logistic
regression analysis to evaluate whether type of substance
use was a determinant of 1) continued treatment for
substance use problems by the GP alone and 2) a mix of
GP and non-GP treatment. Multinomial analysis of five
categories of treatment status at follow-up was excluded
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due to small cell numbers. All patient population charac-
teristics that were significantly (p < 0.05) associated with
the dependent variables were included in both the full
models except work status and work problems in order to
avoid overadjustment bias [20]. A generalised estimating
equation approach was used to account for the clustering
of data within general practices. All possible interaction
effects between independent variables were tested. Data
were analysed with Stata 13.
Results
Study data flow
At baseline 479 general practice patients receiving treat-
ment for substance use problems were recorded (Fig. 1.
Study data flow). No follow-up data were reported for
83 patients, resulting in a study drop-out of 17.3%. Study
drop-out was not significantly associated with any of the
baseline patient characteristics or with the SGP region
(data not shown). A median follow-up reporting delay of
66 days (interquartile range (IQ) 47–77) was observed,
resulting in a median follow-up time of 7 months. There
was no significant association between delay of follow-
up and treatment status at follow-up (data not shown).
Missing data and inclusion of patients without specific
substance-related problems
Missing data exceeding 1% were observed for the length
of problematic substance use in years (22.1%), whether
this was the first treatment episode (8.8%), occupational
status (4.4%) and whether this was a new treatment epi-
sode (3.1%) (Table 1).
No single substance-related problem was reported
from 13 patients (2.7%).
Type of substance use and related characteristics
Significant regional differences were found for type of
substance use, abstinence from substances in the four
weeks preceding the baseline encounter, length of prob-
lem use, occurrence of physical substance-related prob-
lems and treatment status at follow-up (Table 1).
Problems of alcohol alone were significantly more preva-
lent in Flanders compared to Wallonia-Brussels, where
problems of heroin or methadone were much more
important (see Additional file 1: Table S1).
One hundred and ten of 233 (47%) patients with phys-
ical problems had gastro-intestinal problems (Table 1).
The odds of physical problems were significantly higher
among patients in Flanders (odds ratio (OR) 1.66; 95%
CI 1.01–2.73), even after adjustment for type of sub-
stance use (data not in table). The odds of a long history
of substance use problems (≥10 years) were borderline
significantly higher for patients in Wallonia-Brussels
(OR 1.75; 95% CI 1.00–3.10) after adjustment for type of
substance use (data not in table). The odds of recent
abstinence remained significantly higher in Wallonia-
Brussels (OR 2.01; 95% CI 1.42–3.10), independent of
type of substance use (data not in table).
Fig. 1 Study data flow
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Table 1 Patient population characteristics by region (N = 479)
Flanders (N = 268) Wallonia & Brussels
(N = 211)
Belgium (N = 479)
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Men (versus women) 177/267 66.3 (60.3–71.9) 138/207 66.7 (59.8–73.0) 315/474 66.5 (62.0–70.7)
Age in years
<25 16/268 6.0 (3.5–9.5) 8/211 3.8 (1.7–7.3) 24/479 5.0 (3.2–7.4)
25–34 40/268 14.9 (10.9–19.8) 42/211 19.9 (14.7–25.9) 82/479 17.1 (13.9–20.8)
35–44 50/268 18.7 (14.2–23.8) 46/211 21.8 (16.4–28.0) 96/479 20.0 (16.5–23.9)
45–54 102/268 38.1 (32.2–44.2) 64/211 30.3 (24.2–37.0) 166/479 34.7 (30.4–39.1)
55–64 60/268 22.4 (17.5–27.9) 51/211 24.2 (18.6–30.5) 111/479 23.2 (19.5–27.2)
Type of substance use
Alcohol alone 142/268 53.0 (46.8–59.1) 84/211 39.8 (33.1–46.8) 226/479 47.2 (42.6–51.8)
Prescription drugs 53/268 19.4 (14.8–24.7) 44/211 20.9 (15.6–27.0) 97/479 20.3 (16.5–23.9)
Illicit drugs, excluding heroin
and methadone
54/268 20.1 (15.5–25.5) 26/211 12.3 (8.2–17.5) 80/479 16.7 (13.5–20.3)
Heroin or methadone 19/268 7.1 (4.3–10.9) 57/211 27.0 (21.1–33.5) 76/479 15.9 (12.7–19.5)
Substance use characteristics
Abstinence from substances
in last 4 weeks
108/268 40.3 (34.4–46.4) 118/211 55.9 (48.9–62.7) 226/479 47.2 (42.6–51.8)
Single substance use 178/268 66.4 (60.4–72.0) 127/211 60.2 (53.2–61.8) 305/479 63.7 (59.2–68.0)
Problematic use ≥10 years 102/209 48.8 (41.8–56.0) 111/164 67.9 (59.9–74.8) 213/373 57.1 (51.9–62.2)
Substance-related problems
Physical problems 149/268 55.6 (49.4–61.6) 84/211 39.8 (33.2–46.8) 233/479 48.6 (44.1–53.2)
Mental problems 206/268 76.9 (71.3–81.8) 172/211 81.5 (75.6–86.5) 378/479 78.9 (75.0–82.5)
Problems at work 61/268 22.8 (17.9–28.3) 30/211 14.2 (9.8–19.7) 91/479 19.0 (15.6–22.8)
Social problems 198/268 73.9 (68.1–79.0) 153/211 72.5 (59.0–78.4) 351/479 73.3 (69.1–77.2)
Occupational status: at work 114/253 45.1 (38.8–51.4) 66/205 32.2 (25.9–39.1) 180/458 39.3 (34.8–43.9)
Treatment history
First treatment episode 66/249 26.5 (21.1–32.4) 39/188 20.7 (15.2–27.2) 105/437 24.0 (20.1–28.3)
Ongoing treatment episode 154/254 60.6 (54.3–66.7) 150/210 71.4 (64.8–77.4) 304/464 65.5 (61.0–69.8)
Treatment status at follow-up
1) Study drop-out, treatment
drop-out or deceaseda
93/268 34.7 (29.0–40.7) 64/211 30.3 (24.2–37.0) 157/479 32.8 (28.6–37.2)
2) Discontinued GP treatment 91/268 34.0 (28.3–40.0) 48/211 22.7 (17.3–29.0) 139/479 29.0 (25.0–33.3)
3) Continued (usual) GP treatment,
substance use treatment by non-GP
19/268 7.1 (4.3–10.9) 9/211 4.3 (2.0–7.9) 28/479 5.8 (3.9–8.3)
4) Continued substance use treatment
by GP & non-GP
33/268 12.3 (8.6–16.9) 40/211 19.0 (13.9–24.9) 73/479 15.2 (12.1–18.8)
5) Continued substance use treatment
by GP alone
32/268 11.9 (8.3–16.4) 50/211 23.7 (18.1–30.0) 82/479 17.1 (13.9–20.8)
Continued GP treatment (total of 3 to 5) 84/268 31.3 (25.8–37.3) 99/211 46.9 (40.0–53.9) 183/479 38.2 (33.8–42.7)
Continued GP substance use treatment
(total of 4 and 5)
65/268 24.3 (19.2–29.8) 90/211 42.7 (35.9–49.6) 155/479 32.4 (28.2–36.8)
CI Confidence interval. (Borderline) non-overlapping confidence intervals are in bold
a5 of 479 patients were deceased, 2 deaths were caused by substance use
Missing data: gender: n = 5 (1.0%); age: n = 0; substances used: n = 0; length of use: n = 106 (22.1%); occupational status: n = 21 (4.4%); first treatment: n = 42
(8.8%); ongoing treatment episode: n = 15 (3.1%)
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Patient status at follow-up
The total drop-out rate of 32.8% (157 of 479 patients)
includes study drop-out (n = 83), treatment drop-out
(n = 69) and patients’ death (n = 5) (Fig. 1 and Table 1).
The treatment discontinuation rate was 29%, in other
words, 139 of 479 patients had at least one GP encounter
during the study period but not in the four weeks before
the follow-up report. The total treatment continuation
rate of 38.2% means that 183 of 479 patients continued
GP substance use treatment during the study period, i.e.
they had a GP encounter in the four weeks before follow-
up reporting. The smallest part of the GP treatment con-
tinuation group (28 patients, 5.8%) received treatment as
usual by their GP and substance use treatment by a spe-
cialised caregiver. Seventy-three patients (15.2%) received
substance use treatment by their GP and a non-GP care-
giver and 82 patients (17.1%) received substance use treat-
ment by their GP alone.
Continued substance use treatment by a GP, alone or
mixed with non-GP treatment, was higher among users
of heroin or methadone, patients with an ongoing treat-
ment episode and patients in Wallonia-Brussels (Table 2).
The adjusted model revealed that type of substance use
is not an independent determinant of continued sub-
stance use treatment by a GP (alone or mixed), only the
region is (Table 3).
Continued substance use treatment by a GP alone was
higher among patients between 45 and 54 years, lower
among patients aged 25 to 34 years and equally higher
in Wallonia-Brussels (Table 2).
The adjusted model showed an interaction between
type of substance use and region. In the Flemish popula-
tion, the odds for continued substance use treatment by
the GP alone were higher for patients with problematic
use of prescription drugs and patients with problems of
heroin or methadone (Table 4). No significant model of
determinants of continued substance use treatment by the
GP alone could be developed for the Walloon-Brussels
population.
Discussion
Main findings
This pilot shows positive results regarding the feasibility
of a continuous surveillance of treated substance use
problems by the SGP. Few variables had more than 1%
missing values. The negligible percentage of patients
from whom no substance-related problems were re-
ported suggests a clear understanding of the concept of
“problematic use of substances”. The usefulness of a
continuous surveillance is suggested by the profile and
magnitude of the population. The Belgian general prac-
tice population that is treated for substance use prob-
lems is characterized by problems of mono-substance
use, mostly of alcohol alone. One third of the patients
received continued substance use treatment by their GP
during the study period, be it by their GP alone or by
their GP and a non-GP caregiver. The different profile of
general practice patients compared to patients treated in
specialised care settings was confirmed. As described in
the introduction, general practice patients, known to be
relatively old and female, have less severe problems.
Problems of alcohol alone are less complex than poly-
drug use, according to experiences of GPs and according
to patient-related and substance-related characteristics.
Half of the population had these problems for 10 years
or more and for three quarter of the patients this was
not the first treatment. The latter two findings confirm
the chronic character of substance use problems in the
general practice population.
As expected, we found important regional differences.
In Flanders, more than half of the population had
problems of alcohol alone while problems of heroin or
methadone were more prevalent in Wallonia-Brussels.
Treatment continuation was significantly higher in
Wallonia-Brussels compared to Flanders. Given its higher
level of urbanization, Flanders counts more specialised
centres and pharmacies providing OST than Wallonia. A
previous study confirmed that OST is mostly supplied by
specific, low threshold services in Flanders, while it is
mainly offered by GPs in the French community [21].
Although problems of alcohol alone were more prevalent
among patients in Flanders (53.0%), their prevalence was
similarly considerable in Wallonia-Brussels (39.8%).
Strengths and weaknesses
As far as we know this is the first nationwide study in
Belgium assessing the profile and magnitude of the adult
general practice population with treated substance use
problems. It is based on usual care data reported by
members of a long-standing, multi-subject and represen-
tative network of SGP. Provider-reported data are com-
monly used in epidemiological research on substances
use. They offer information on hidden and socially stig-
matised populations and can be done on rather low
budgets [22]. This study includes a reasonable sample
size and has a relatively low and unbiased rate of drop-
outs. We succeeded in overcoming the problem of
under-recognition and under-reporting of substance use
problems by GPs by focussing on treated, thus acknowl-
edged, problems. We demonstrated the importance of
confounder control at the health system level when
using treatment-based data to estimate the epidemiology
of problems.
This study has several weaknesses. Our study does not
include people with untreated substance use problems,
and many people with alcohol problems do not seek treat-
ment [23]. Instructions and definitions presented to the
SGP participants were brief since the annual surveillance
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program comprises multiple health problems. One ex-
ample is that we did not define when a treatment episode
starts or ends. The two main measures, type of substance
use and patient (treatment) status at follow-up, lack
detailed information. We do not know if methadone was
misused or used as prescribed by the GP, and if this pre-
scription was intended for intoxication or for mainten-
ance. Almost all patients were found to have at least one
substance-related problem but the clinical diversity of the
population is large. Yet, not only do patients with sub-
stance use problems form a heterogeneous group, so do
their GPs and their interventions. Moreover, facts and
views on problematic substance use are inseparable from
the care setting. Problem use of tranquillizers and seda-
tives is undoubtedly much more common among general
practice patients than is the non-medical use or misuse of
prescription drugs by illicit drug users, e.g. heroin users.
These aforementioned weaknesses are largely due to the
use of provider-reported, care-based data. Another set of
weaknesses is related to the pilot character of the study.
The short study period relative to the large number of
measures resulted in insufficient statistical power to apply
Table 2 Rates of continued GP substance use treatment, respectively by the GP alone or mixed with non-GP treatment, and by the
GP alone, according to patient characteristics
Continued substance use treatment by GP
(alone or mixed with non-GP)
Continued substance use treatment by GP alone
Yes (n = 155) No (n = 324)a Yes (n = 82) No (n = 397)b
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Men (versus women) 96/154 62.3 (54.2–70.0) 219/320 68.4 (63.0–73.5) 55/82 67.0 (55.8–77.1) 260/392 66.3 (61.4–71.0)
Age in years
<25 7/155 4.5 (1.8–9.1) 17/324 5.2 (3.1–8.3) 1/82 1.2 (0.3–6.6) 23/397 5.8 (3.7–8.6)
25–34 22/155 14.2 (9.1–20.7) 60/324 18.5 (14.4–23.2) 4/82 4.9 (1.3–12.0) 78/397 19.6 (15.9–23.9)
35–44 34/155 21.9 (15.7–29.3) 62/324 19.1 (15.0–23.8) 20/82 24.4 (15.6–35.1) 76/397 19.6 (15.9–23.9)
45–54 61/155 39.4 (31.6–47.5) 105/324 32.4 (27.3–37.8) 39/82 47.6 (36.4–58.9) 127/397 32.0 (27.4–36.8)
55–64 31/155 20.0 (14.0–27.2) 80/324 24.7 (20.1–29.8) 18/82 22.0 (13.6–32.5) 93/397 23.4 (19.3–27.9)
Type of substance use
Alcohol alone 64/155 41.3 (33.5–49.5) 162/324 50.0 (44.4–55.6) 33/82 40.2 (9.6–51.7) 193/397 48.6 (43.6–53.7)
Prescription drugs 36/155 23.2 (16.8–30.7) 61/324 18.5 (14.4–23.2) 25/82 30.5 (20.8–41.6) 72/397 17.9 (14.2–22.0)
Illicit drugs, excl. heroin and
methadone
18/155 11.6 (7.0–17.7) 62/324 19.1 (15.0–23.8) 8/82 9.8 (4.3–18.3) 72/397 18.1 (14.5–22.3)
Heroin or methadone 37/155 23.9 (17.4–31.4) 39/324 12.0 (8.7–16.1) 16/82 19.5 (11.6–29.7) 60/397 15.1 (11.7–19.0)
Substance use characteristics
Abstinence in last 4 weeks 76/155 49.0 (40.9–57.2) 150/324 46.3 (40.8–51.9) 44/82 53.7 (42.3–64.7) 182/397 45.8 (40.9–50.9)
Single substance use 94/155 60.6 (52.5–68.4) 211/324 65.1 (59.7–70.3) 58/82 70.7 (59.6–80.3) 247/397 62.2 (57.2–67.0)
Problematic use ≥10 years 70/155 57.9 (48.5–66.8) 143/324 56.7 (50.4–62.9) 36/82 56.3 (43.3–68.6) 177/309 57.3 (51.6–62.9)
Substance use related problems
Physical problems 71/155 45.8 (37.8–54.0) 162/324 50.0 (44.4–55.6) 37/82 45.1 (34.1–56.5) 196/397 49.4 (44.3–54.4)
Mental problems 129/155 83.2 (76.4–88.7) 249/324 76.9 (71.9–81.3) 68/82 82.9 (73.0–90.3) 310/397 78.1 (73.7–82.1)
Problems at work 26/155 16.8 (11.3–23.6) 65/324 20.1 (15.8–24.8) 8/82 9.8 (4.3–18.3) 83/397 20.9 (17.0–25.2)
Social problems 118/155 76.1 (68.6–82.6) 233/324 71.9 (66.7–76.7) 62/82 75.6 (64.9–84.4) 289/397 72.9 (68.1–77.1)
Occupational status: at work 47/155 31.5 (24.2–39.7) 133/309 43.0 (37.4–48.8) 27/82 34.6 (24.2–46.2) 153/380 40.3 (35.3–45.4)
Treatment history
First treatment episode 32/155 21.6 (15.3–29.1) 73/289 25.3 (20.4–30.7) 22/82 27.2 (18.3–39.1) 83/358 23.2 (18.9–27.9)
Ongoing treatment episode
(versus new)
39/155 74.8 (67.2–81.5) 188/309 60.8 (55.2–66.3) 20/82 75.6 (64.9–84.4) 242/382 63.4 (58.3–68.2)
Wallonia-Brussels (versus Flanders) 90/155 58.1 (49.9–65.9) 121/324 37.3 (32.1–42.9) 50/82 61.0 (49.6–71.6) 161/397 40.6 (35.7–45.6)
CI Confidence interval. Non-overlapping confidence intervals are in bold
aThis subpopulation includes all other patients, i.e. dropped-out or deceased patients, patients who discontinued GP treatment and patients who continued usual
GP treatment without GP substance use treatment
bThis subpopulation includes all other patients, i.e. dropped-out or deceased patients, patients who discontinued GP treatment, and patients who continued GP
treatment combined with non-GP treatment
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optimal analysis such as multinomial analysis of all cat-
egories of patient status at follow-up. A second example is
that we were unable to adjust for individual substances in
the model exploring determinants of continued substance
use treatment by a GP. The data were collected only by
part of the SGP network and over a limited time period.
The study sample may be biased towards SGP with rela-
tively more experience with substance use problems. We
may have missed patients treated in a residential setting
and thus unable to visit their GP in the short study period.
In future, this potential bias may be overcome by asking
SGP to report any follow-up information about the pa-
tient, including information from other caregivers.
Comparison with evidence (from literature)
It would make little sense to compare our findings with
the 2012 TDI report describing new treatment episodes
only from the treatment centres under contract with the
National Institute for Health and Disability Insurance
(NIHDI) [24]. Neither is it easy to compare our findings
with findings from the general population. The Belgian
Health Interview Survey 2013 does not allow regional
comparisons because of the relatively low use of (illicit)
drugs in the general population [7]. It shows no regional
differences in problematic alcohol consumption by
people aged 18–64 years, according to three indicators
of alcohol consumption (lifetime problematic drinking
based on CAGE 2+, daily drinkers with hazardous drink-
ing habit and weekly consumption of 6+ drinks per oc-
casion). However, alcohol-related premature mortality
exhibits a clear-cut regional divide with higher rates in
Wallonia and Brussels and lower rates in Flanders [25].
For some study findings we did not find a straightfor-
ward explanation. In Wallonia-Brussels, fewer patients
suffered from substance-related physical problems despite
a longer history of use. Recent abstinence of substances
remained higher in the latter region, independent of type
of substance use.
Implications
Our findings suggest that general practice should be
taken into account to provide an indicator of treatment
demand since 17% of the SGP population was treated by
their GP alone during the study period. Yet, the SGP
study period was less than one year and eventually all
general practice patients from our sample may have
started a new treatment episode in a non-general prac-
tice setting in the course of 2013. The relatively large
proportion of missing values for the length of use in
years may be diminished by grouping years in categories
on the registration form. The Belgian TDI register
equally shows a rather large proportion of missing values
for the variable first treatment [24]. Ideally, a continuous
surveillance by the network of SGP should follow the
TDI protocol as closely as possible without overloading
busy GPs with instructions. In the near future, it will be
theoretically possible to measure overlap between the
two databases (SGP and TDI) at the patient level by
using unique patient identifiers. The organisation of data
exchange in the Belgian health care setting according to
the principle of a single multifunctional data collection is
now ongoing through the implementation of the E-health
roadmap (http://www.rtreh.be/EHEALTH/_images/20130
419actieplan_egezondheidnl.pdf).
Conclusions
A continuous surveillance of the general practice popu-
lation treated for substance use problems seems to be
feasible and useful. The usefulness is evidenced by the
profile and the relative magnitude of the population.
Both study measures show large inter-regional differ-
ences that are likely to be associated with differences in
health services organisation. These differences in treat-
ment delivery should be taken into account when
Table 3 Adjusted odds ratios for continued substance use
treatment by the GP alone or mixed with non-GP treatment
(n = 459)
OR (95% CI)
Median age or older (versus <median) 1.03 (0.62–1.71)
Men (versus women) 0.79 (0.49–1.29)
Type of substance use
Alcohol alone reference
Prescription drugs 1.40 (0.81–2.42)
Illicit drugs, excluding heroin and methadone 0.85 (0.47–1.51)
Heroin or methadone 1.59 (0.80–3.16)
Ongoing treatment episode (versus new) 1.57 (0.97–2.53)
Wallonia-Brussels (versus Flanders) 1.97 (1.16–3.34)
OR Odds ratio, CI Confidence interval. Non-overlapping confidence intervals
are in bold
Table 4 Adjusted odds ratios for continued substance use
treatment by the GP alone in Flandersa (n = 267)
OR (95% CI)
Median age or older (versus <median) 2.44 (0.96–6.25)
Men (versus women) 0.82 (0.36–1.87)
Type of substance use
Alcohol alone reference
Prescription drugs 4.04 (1.65–9.94)
Illicit drugs, excluding heroin and methadone 0.78 (0.15–4.10)
Heroin or methadone 6.64 (1.76–25.06)
OR Odds ratio, CI Confidence interval. Non-overlapping confidence intervals
are in bold
aIn the overall model of determinants of GP treatment alone, there is a
significant interaction between region and type of substance use. Modeling
determinants in populations split by region resulted in a non-significant model
in Wallonia-Brussels (n = 207)
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estimating the epidemiology of substance use problems
among general practice patients.
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